WallStSmart

American Tower Corp (AMT)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

American Tower Corp generates 158534% more annual revenue ($10.82B vs $6.82M). AMT leads profitability with a 26.8% profit margin vs -40.7%. AMT earns a higher WallStSmart Score of 72/100 (B).

AMT

Strong Buy

72

out of 100

Grade: B

Growth: 6.7Profit: 9.0Value: 5.3Quality: 3.0
Piotroski: 4/9Altman Z: 0.36

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMTUndervalued (+7.0%)

Margin of Safety

+7.0%

Fair Value

$194.13

Current Price

$194.12

$0.01 discount

UndervaluedFair: $194.13Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMT5 strengths · Avg: 9.6/10
Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Operating MarginProfitability
45.9%10/10

Strong operational efficiency at 45.9%

EPS GrowthGrowth
76.9%10/10

Earnings expanding 76.9% YoY

Market CapQuality
$86.44B9/10

Large-cap with strong market position

Profit MarginProfitability
26.8%9/10

Keeps 27 of every $100 in revenue as profit

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

AMT4 concerns · Avg: 3.0/10
PEG RatioValuation
1.974/10

Expensive relative to growth rate

P/E RatioValuation
29.9x4/10

Moderate valuation

Price/BookValuation
25.7x2/10

Trading at 25.7x book value

Altman Z-ScoreHealth
0.362/10

Distress zone — elevated risk

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$48.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-2.53M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : AMT

The strongest argument for AMT centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 26.8% and operating margin at 45.9%.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : AMT

The primary concerns for AMT are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 12.36 is elevated, increasing financial risk.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

AMT profiles as a mature stock while EUDA is a hypergrowth play — different risk/reward profiles.

AMT carries more volatility with a beta of 0.90 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

AMT generates stronger free cash flow (951M), providing more financial flexibility.

Bottom Line

AMT scores higher overall (72/100 vs 24/100), backed by strong 26.8% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

American Tower Corp

REAL ESTATE · REIT - SPECIALTY · USA

American Tower Corporation (also referred to as American Tower or ATC) is an American real estate investment trust and an owner and operator of wireless and broadcast communications infrastructure in several countries worldwide and is headquartered in Boston, Massachusetts.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.

Visit Website →

Want to dig deeper into these stocks?